Abstract 9461: Circulating CD14+CD16+ Monocyte Subsets as Biomarkers for Severity of Coronary Artery Disease in Patients With Stable Angina Pectoris
Background: Circulating monocytes can be divided into two subsets typically identified by the expression of CD14 and CD16. Although previous studies have shown that circulating monocytes contribute to the progression of coronary atherosclerotic lesions, the relationship between the severity of coronary artery disease (CAD) and the two distinct monocyte subsets has not previously been evaluated. We investigated the relationship between monocyte subsets and severity of CAD assessed by coronary angiography (CAG) in patients with stable angina pectoris (SAP).
Methods: We enrolled 125 patients who underwent diagnostic CAG. Patients were divided into three groups; those without CAD, those with single-vessel disease (SVD), and those with multiple-vessel disease (MVD), according to diagnostic CAG findings. In addition, severity of CAD was evaluated by Gensini score. Two monocyte subsets (CD14+CD16- and CD14+CD16+) were measured by flow cytometry.
Results: Circulating CD14+CD16+ monocytes were more frequently observed in patients with MVD (24.4 [18.5 to 29.8] %) than in those with SVD (vs. 12.8 [10.0 to 16.2] %, p<0.001) or without CAD (vs. 8.9 [7.6 to 10.2] %, p<0.001). High-sensitivity C-reactive protein and soluble CD40 ligand were not significantly different among the three groups. The proportion of CD14+CD16+ monocytes was positively correlated with Gensini score (r=0.618, p<0.001). Multivariate logistic regression analysis revealed that the preferential increase of CD14+CD16+ monocytes was an independent predictor of MVD ((odds ratio: 1.475; 95% confidence interval: 1.273 to 1.708, p<0.001).
Conclusions: Our results revealed that the increased proportion of CD14+CD16+ monocytes associated with severity of CAD in patients with SAP. Preferential increase in peripheral CD14+CD16+ monocytes might closely relate to the pathophysiology of CAD progression.
- © 2012 by American Heart Association, Inc.